DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Canada
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
REUN logo

Reunion Neuroscience Inc. Stock Price

TSX:REUN Community·CA$16.6m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

REUN Share Price Performance

CA$0
0.00 (0.00%)
​
CA$0
0.00 (0.00%)
​
Price CA$0
Fri, 11 Sep 26
Share Pricen/a

REUN Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Adequate balance sheet and slightly overvalued.

6 Risks
0 Rewards
View Full Analysis

Reunion Neuroscience Inc. Key Details

CA$0

Revenue

CA$0

Cost of Revenue

CA$0

Gross Profit

CA$38.1m

Other Expenses

-CA$38.1m

Earnings

Last Reported Earnings
Mar 31, 2023
Next Reporting Earnings
n/a
-3.25
0%
0%
0%
View Full Analysis

About REUN

Founded
2008
Employees
16
CEO
Gregory Mayes
WebsiteView website
reunionneuro.com

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company’s lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.

Recent REUN News & Updates

Recent updates

No updates

Reunion Neuroscience Inc. Competitors

BNXT logo

BioNxt Solutions

Symbol: CNSX:BNXT
Market cap: CA$45.6m
EPIC logo

1CM

Symbol: CNSX:EPIC
Market cap: CA$45.3m
BCT logo

BriaCell Therapeutics

Symbol: TSX:BCT
Market cap: CA$43.9m
SHRX logo

Sharp Therapeutics

Symbol: TSXV:SHRX
Market cap: CA$43.3m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide